Jones v. Invasix Inc.

CourtDistrict Court, M.D. Tennessee
DecidedMay 19, 2020
Docket3:19-cv-00860
StatusUnknown

This text of Jones v. Invasix Inc. (Jones v. Invasix Inc.) is published on Counsel Stack Legal Research, covering District Court, M.D. Tennessee primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jones v. Invasix Inc., (M.D. Tenn. 2020).

Opinion

UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF TENNESSEE NASHVILLE DIVISION

MIA JONES, ) ) Plaintiff, ) ) v. ) Case No. 3:19-cv-0860 ) Judge Aleta A. Trauger INVASIX INC. and INMODE LTD., ) ) Defendants. ) )

MEMORANDUM

Invasix Inc. (“Invasix”) has filed a Motion to Dismiss (Docket No. 67), to which Mia Jones has filed a Response (Docket No. 75), and Invasix has filed a Reply (Docket No. 81). InMode Ltd. (“InMode”) has filed a separate Motion to Dismiss (Docket No. 69), to which Jones has filed a Response (Docket No. 74), and InMode has filed a Reply (Docket No. 82). Jones filed a Motion for Leave to File a Second Amended Complaint (Docket No. 73), to which Invasix and InMode have jointly filed a Response (Docket No. 83), and Jones has filed a Reply (Docket No. 84). For the reasons set out herein, Jones’ motion will be granted, InMode’s motion will be granted in part and denied in part as moot, and Invasix’s motion will be denied as moot. I. BACKGROUND1 “The Medical Device Amendments of 1976 (‘MDA’), 21 U.S.C. §§ 360c–360k, 379–379a, establishes the framework for federal regulation of medical devices. As amended, the MDA requires the FDA to place a device into one of three classes reflecting different levels of regulation.” Kaiser v. Johnson & Johnson, 947 F.3d 996, 1003 (7th Cir. 2020). “The devices receiving the most federal oversight are those in Class III, which include,” among other things, “replacement heart valves, implanted cerebella stimulators, and pacemaker pulse generators.” Riegel v. Medtronic, Inc., 552 U.S. 312, 317 (2008). A device is placed in Class III based on the risk entailed in its use and the lack of available information ensuring that it can be safely sold without prior review for safety and effectiveness. See 21 U.S.C. § 360c(a)(1)(C).

Generally speaking, Class III medical devices are subject to a “rigorous regime of premarket approval” administered by the FDA. Riegel, 552 U.S. at 317. In certain defined situations, however, it is permissible to bring a Class III device to market without completing the full FDA approval process. Specifically, the MDA “grandfathered many [devices] that were already on the market,” allowing those devices to “remain on the market until the FDA promulgates, after notice and comment, a regulation requiring premarket approval.” Id. (citing 21 U.S.C. §§ 360c(f)(1), 360e(b)(1)). The MDA’s grandfathering provision applies not only to the specific devices that pre-dated the MDA, but also any “substantially equivalent” devices. Id. If a company seeks to sell a Class III device as “substantially equivalent” to a grandfathered device, it must submit the device to an FDA review “known as the § 510(k) process, named after

the statutory provision describing the review.” Id. Although the § 510(k) process does entail submitting the device to some degree of regulatory scrutiny, it is generally understood that a § 510(k) review, because it is focused only on substantial equivalence, will be less comprehensive and onerous than a premarket review for a non-grandfathered Class III device. InMode is an Israeli medical device corporation. Invasix is a Canada-based Delaware corporation that allegedly “acts as the North American division” of InMode. (Docket No. 76-12 ¶¶ 6, 17.) InMode and Invasix sell a Class III medical device under the trade name “Fractora,” which, according to Jones, is “designed, manufactured and sold in North America by Invasix.” (Id. ¶ 1.) The Fractora device consists of a console and a handheld applicator, with a disposable tip,

designed to deliver radiofrequency electrical current to human skin. (Id. ¶ 23.) The Fractora device is used to “vaporize columns of skin,” which in turn “stimulates the body’s production of collagen” in order to “leave[] the skin looking and feeling smoother.” (Id. ¶ 24.) Invasix submitted a § 510(k) application for the Fractora device around late May of 2011, and it was ultimately approved as substantially equivalent to a grandfathered device. (Id. ¶ 21 & n.1)

According to Jones, however, the approval of the Fractora as a substantially equivalent device was the result, at least in part, of improper actions by the defendants during the device’s § 510(k) review. In particular, the defendants’ § 510(k) application described the intended application of the Fractora device in a manner that differed, in several key ways, from the uses for which the defendants ultimately marketed the device. (Id. ¶¶ 35–38.) As a result, Jones alleges, the defendants were able to take the least challenging available route to approved sales of a Class III device—intended exclusively for devices that had already been used for many years or slight variations thereon—only to then market the Fractora as a “revolution in medical devices” to be used in dangerous ways that the FDA never considered.2 (Id. ¶ 22.) Jones is an aesthetician who works in the office of Dr. Paulino E. Goco in Nashville. Jones

had a Fractora procedure—in fact, her third Fractora procedure—performed on her face by one of Dr. Goco’s other aestheticians on November 15, 2017. Jones characterizes the procedure as “only to refresh her skin, which was virtually wrinkle-free and healthy-looking.” (Id. ¶ 52.) Earlier, Jones and other aestheticians from the office had met with Invasix representatives and an Invasix trainer. These representatives assured Jones and other aestheticians that the Fractora procedure “was an extremely safe, painless and non-invasive alternative to face lift and [laser] procedures.” (Id. ¶ 53.) The representatives told Jones that “the procedure was risk-free and would require little

2 Jones alleges several additional types of wrongdoing related to the promotion of the Fractora device. The details of those allegations are immaterial to the issues presented by the pending motions . downtime.” (Id.) They also recommended that aestheticians perform the procedures, despite the fact that Fractora had only been approved for use by physicians. (Id. ¶ 54.) Neither of the Fractora procedures that Jones underwent prior to November 15, 2017, had resulted in any unexpected ill effects. For the third procedure, however, the aesthetician slightly

changed the treatment parameters by using a different tip, the “60 pin tip.” (Id. ¶¶ 55–56.) Jones and the other aesthetician, Tricia King, selected that tip based on training they had received from Invasix and an Invasix-published Quick Reference Guide. (Id. ¶ 57.) The procedure “left Mia’s face extremely red and a little swollen even after using a cooling device,” after which she began scabbing. Due to the “condition of her face,” she took three days off of work. (Id. ¶ 56.) According to her proposed Second Amended Complaint, Jones “first became concerned her injury was beyond that intended by the procedure when her condition worsened over the next few months.” (Id. ¶ 63.) On January 8, 2018, she saw a physician, Dr. Natalie Curcio, with whom she discussed the situation. According to Dr. Curcio’s notes, she suggested that Jones not undergo any new procedure to attempt to address the results of the treatment and instead wait, for the time

being, to see how she continued to heal. (Id.) In April of 2018, Jones saw another physician, Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Foman v. Davis
371 U.S. 178 (Supreme Court, 1962)
Volkswagenwerk Aktiengesellschaft v. Schlunk
486 U.S. 694 (Supreme Court, 1988)
Sanchez-Llamas v. Oregon
548 U.S. 331 (Supreme Court, 2006)
Riegel v. Medtronic, Inc.
552 U.S. 312 (Supreme Court, 2008)
Sandra S. Smith v. Ted W. Sushka
117 F.3d 965 (Sixth Circuit, 1997)
Linda K. Brumbalough v. Camelot Care Centers, Inc.
427 F.3d 996 (Sixth Circuit, 2005)
Sherrill v. Souder
325 S.W.3d 584 (Tennessee Supreme Court, 2010)
John Kohl & Co. PC v. Dearborn & Ewing
977 S.W.2d 528 (Tennessee Supreme Court, 1998)
Stanbury v. Bacardi
953 S.W.2d 671 (Tennessee Supreme Court, 1997)
Bishop v. Lucent Technologies, Inc.
520 F.3d 516 (Sixth Circuit, 2008)
Thompson v. Kerr
555 F. Supp. 1090 (S.D. Ohio, 1982)
Shadrick v. Coker
963 S.W.2d 726 (Tennessee Supreme Court, 1998)
Wyatt v. A-Best, Company
910 S.W.2d 851 (Tennessee Supreme Court, 1995)
Cataldo v. United States Steel Corp.
676 F.3d 542 (Sixth Circuit, 2012)
Metropolitan Alloys Corp. v. State Metals Industries, Inc.
416 F. Supp. 2d 561 (E.D. Michigan, 2006)
McCann v. Foster Wheeler LLC
225 P.3d 516 (California Supreme Court, 2010)
Water Splash, Inc. v. Menon
581 U.S. 271 (Supreme Court, 2017)
Barbara Kaiser v. Johnson & Johnson
947 F.3d 996 (Seventh Circuit, 2020)

Cite This Page — Counsel Stack

Bluebook (online)
Jones v. Invasix Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/jones-v-invasix-inc-tnmd-2020.